ImmuPharma (LON:IMM) Stock Price Down 6.3% - What's Next?

Key Points

• ImmuPharma plc shares fell by 6.3%, closing at GBX 11.60 ($0.15), with a significant decline in trading volume of 53% compared to the average.
• The company's market capitalization is £58.32 million, with a PE ratio of -13.03 and a reported EPS of GBX (0.38) for the last quarter.
• ImmuPharma is known for its peptide-based therapeutics, focusing on autoimmune diseases and has a lead program called P140 (Lupuzor™) aimed at treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price fell 6.3% during trading on Friday . The company traded as low as GBX 10.70 ($0.14) and last traded at GBX 11.60 ($0.15). 3,961,091 shares changed hands during trading, a decline of 53% from the average session volume of 8,360,403 shares. The stock had previously closed at GBX 12.38 ($0.16).

ImmuPharma Trading Down 6.3%

The company has a market cap of £58.32 million, a P/E ratio of -13.03 and a beta of 1.53. The firm's 50 day moving average price is GBX 8.75 and its 200-day moving average price is GBX 4.62.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.